Revolo Biotherapeutics, a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, has entered into a Master Service Agreement with CordenPharma, for the production of Revolo Bio’s first-in-class peptide and immune system resetting drug product, ‘1104, to support upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease.
 
CordenPharma is fully equipped to manufacture peptide Active Pharmaceutical Ingredients (APIs) for the clinical supplies of future studies and to serve as an ongoing commercial supply partner.
 
“CordenPharma is a world leader in the development, scale-up and manufacturing of chemically synthesized APIs, making it an ideal manufacturing partner for ‘1104,” said Jonathan Rigby, group chief executive officer of Revolo Bio. “With this partnership, we are ready to ramp-up and scale-up manufacturing to support our two upcoming Phase 2 trials, which we plan to initiate before the end of 2021. We look forward to further evaluating ‘1104’s ability to reset the immune system to potentially provide patients with a revolutionary treatment option that achieves long-term disease remission without immune system suppression.”
 
CordenPharma chief executive officer Dr. Michael Quirmbach commented, “The CordenPharma team is looking forward to growing this ongoing commercial supply partnership with Revolo Bio, starting with the manufacture of peptide APIs for their upcoming clinical trials. We are hopeful these important studies will lead to critical life-saving medications for their patients.”
 
Under the terms of the agreement, CordenPharma will manufacture ‘1104 following Current Good Manufacturing Practices (cGMP) at its facility in Boulder, Colorado.